Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.

Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA.

Br J Cancer. 2018 Oct 15. doi: 10.1038/s41416-018-0278-4. [Epub ahead of print]

PMID:
30318513
2.

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.

Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA.

Clin Cancer Res. 2018 Aug 14. doi: 10.1158/1078-0432.CCR-17-1118. [Epub ahead of print]

PMID:
30108102
3.

Following anticancer drug activity in cell lysates with DNA devices.

Kahanda D, Singh N, Boothman DA, Slinker JD.

Biosens Bioelectron. 2018 Nov 15;119:1-9. doi: 10.1016/j.bios.2018.07.059. Epub 2018 Jul 30.

PMID:
30098460
4.

Modulators of Redox Metabolism in Head and Neck Cancer.

Chen X, Mims J, Huang X, Singh N, Motea E, Planchon SM, Beg M, Tsang AW, Porosnicu M, Kemp ML, Boothman DA, Furdui CM.

Antioxid Redox Signal. 2017 Dec 20. doi: 10.1089/ars.2017.7423. [Epub ahead of print]

PMID:
29113454
5.

The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.

Silvers MA, Deja S, Singh N, Egnatchik RA, Sudderth J, Luo X, Beg MS, Burgess SC, DeBerardinis RJ, Boothman DA, Merritt ME.

J Biol Chem. 2017 Nov 3;292(44):18203-18216. doi: 10.1074/jbc.M117.813923. Epub 2017 Sep 15.

PMID:
28916726
6.

Genome-Scale Modeling of NADPH-Driven β-Lapachone Sensitization in Head and Neck Squamous Cell Carcinoma.

Lewis JE, Costantini F, Mims J, Chen X, Furdui CM, Boothman DA, Kemp ML.

Antioxid Redox Signal. 2018 Oct 1;29(10):937-952. doi: 10.1089/ars.2017.7048. Epub 2017 Sep 14.

PMID:
28762750
7.

Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery.

Zhou Y, Dong Y, Huang G, Wang Y, Huang X, Zhang F, Boothman DA, Gao J, Liang W.

J Mater Chem B. 2016 Dec 14;4(46):7429-7440. doi: 10.1039/C6TB02049F. Epub 2016 Oct 21.

8.

Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.

Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA.

J Surg Oncol. 2017 Jul;116(1):83-88. doi: 10.1002/jso.24624. Epub 2017 Mar 27.

9.

Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors.

Yan Y, Zhou K, Xiong H, Miller JB, Motea EA, Boothman DA, Liu L, Siegwart DJ.

Biomaterials. 2017 Feb;118:84-93. doi: 10.1016/j.biomaterials.2016.12.001. Epub 2016 Dec 2.

PMID:
27974266
10.

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.

Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA.

Cancer Cell. 2016 Dec 12;30(6):940-952. doi: 10.1016/j.ccell.2016.11.006.

11.

XRN2 Links Transcription Termination to DNA Damage and Replication Stress.

Morales JC, Richard P, Patidar PL, Motea EA, Dang TT, Manley JL, Boothman DA.

PLoS Genet. 2016 Jul 20;12(7):e1006107. doi: 10.1371/journal.pgen.1006107. eCollection 2016 Jul.

12.

Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.

da Cruz EHG, Silvers MA, Jardim GAM, Resende JM, Cavalcanti BC, Bomfim IS, Pessoa C, de Simone CA, Botteselle GV, Braga AL, Nair DK, Namboothiri INN, Boothman DA, da Silva Júnior EN.

Eur J Med Chem. 2016 Oct 21;122:1-16. doi: 10.1016/j.ejmech.2016.06.019. Epub 2016 Jun 14.

13.

The cancer cell 'energy grid': TGF-β1 signaling coordinates metabolism for migration.

Jiang L, Deberardinis R, Boothman DA.

Mol Cell Oncol. 2015 Jan 7;2(3):e981994. doi: 10.4161/23723556.2014.981994. eCollection 2015 Jul-Sep.

14.

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.

Tang KJ, Constanzo JD, Venkateswaran N, Melegari M, Ilcheva M, Morales JC, Skoulidis F, Heymach JV, Boothman DA, Scaglioni PP.

Clin Cancer Res. 2016 Dec 1;22(23):5851-5863. Epub 2016 May 24.

15.

NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.

Li LS, Reddy S, Lin ZH, Liu S, Park H, Chun SG, Bornmann WG, Thibodeaux J, Yan J, Chakrabarti G, Xie XJ, Sumer BD, Boothman DA, Yordy JS.

Mol Cancer Ther. 2016 Jul;15(7):1757-67. doi: 10.1158/1535-7163.MCT-15-0765. Epub 2016 Apr 12.

16.

Galactic cosmic ray simulation at the NASA Space Radiation Laboratory.

Norbury JW, Schimmerling W, Slaba TC, Azzam EI, Badavi FF, Baiocco G, Benton E, Bindi V, Blakely EA, Blattnig SR, Boothman DA, Borak TB, Britten RA, Curtis S, Dingfelder M, Durante M, Dynan WS, Eisch AJ, Robin Elgart S, Goodhead DT, Guida PM, Heilbronn LH, Hellweg CE, Huff JL, Kronenberg A, La Tessa C, Lowenstein DI, Miller J, Morita T, Narici L, Nelson GA, Norman RB, Ottolenghi A, Patel ZS, Reitz G, Rusek A, Schreurs AS, Scott-Carnell LA, Semones E, Shay JW, Shurshakov VA, Sihver L, Simonsen LC, Story MD, Turker MS, Uchihori Y, Williams J, Zeitlin CJ.

Life Sci Space Res (Amst). 2016 Feb;8:38-51. doi: 10.1016/j.lssr.2016.02.001. Epub 2016 Feb 17.

17.

Using DNA devices to track anticancer drug activity.

Kahanda D, Chakrabarti G, Mcwilliams MA, Boothman DA, Slinker JD.

Biosens Bioelectron. 2016 Jun 15;80:647-653. doi: 10.1016/j.bios.2016.02.026. Epub 2016 Feb 12.

18.

The Kub5-Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair.

Patidar PL, Motea EA, Fattah FJ, Zhou Y, Morales JC, Xie Y, Garner HR, Boothman DA.

Nucleic Acids Res. 2016 Feb 29;44(4):1718-31. doi: 10.1093/nar/gkv1492. Epub 2016 Jan 26.

19.

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.

Chakrabarti G, Silvers MA, Ilcheva M, Liu Y, Moore ZR, Luo X, Gao J, Anderson G, Liu L, Sarode V, Gerber DE, Burma S, DeBerardinis RJ, Gerson SL, Boothman DA.

Sci Rep. 2015 Nov 25;5:17066. doi: 10.1038/srep17066.

20.

Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer.

Wang M, Topalovski M, Toombs JE, Wright CM, Moore ZR, Boothman DA, Yanagisawa H, Wang H, Witkiewicz A, Castrillon DH, Brekken RA.

Cancer Res. 2015 Dec 1;75(23):5058-69. doi: 10.1158/0008-5472.CAN-15-0744. Epub 2015 Nov 17.

21.

Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.

Madajewski B, Boatman MA, Chakrabarti G, Boothman DA, Bey EA.

Mol Cancer Res. 2016 Jan;14(1):14-25. doi: 10.1158/1541-7786.MCR-15-0207-T. Epub 2015 Nov 9.

22.

Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH.

Lung Cancer. 2015 Dec;90(3):534-41. doi: 10.1016/j.lungcan.2015.10.008. Epub 2015 Oct 9.

23.

Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.

Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, Zhou Y, Xie Y, Burma S, Scaglioni PP, Cantley LC, DeBerardinis RJ, Kimmelman AC, Lyssiotis CA, Boothman DA.

Cancer Metab. 2015 Oct 12;3:12. doi: 10.1186/s40170-015-0137-1. eCollection 2015.

24.

Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.

Ma X, Moore ZR, Huang G, Huang X, Boothman DA, Gao J.

J Drug Target. 2015;23(7-8):672-80. doi: 10.3109/1061186X.2015.1073296. Review.

PMID:
26453163
25.

Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways.

Chakrabarti G, Gerber DE, Boothman DA.

Clin Pharmacol. 2015 Mar 27;7:57-68. doi: 10.2147/CPAA.S79760. eCollection 2015. Review.

26.

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.

Moore Z, Chakrabarti G, Luo X, Ali A, Hu Z, Fattah FJ, Vemireddy R, DeBerardinis RJ, Brekken RA, Boothman DA.

Cell Death Dis. 2015 Jan 15;6:e1599. doi: 10.1038/cddis.2014.564.

27.

Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.

Ma X, Huang X, Moore Z, Huang G, Kilgore JA, Wang Y, Hammer S, Williams NS, Boothman DA, Gao J.

J Control Release. 2015 Feb 28;200:201-11. doi: 10.1016/j.jconrel.2014.12.027. Epub 2014 Dec 24.

28.

Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks.

Chakraborty S, Li L, Puliyappadamba VT, Guo G, Hatanpaa KJ, Mickey B, Souza RF, Vo P, Herz J, Chen MR, Boothman DA, Pandita TK, Wang DH, Sen GC, Habib AA.

Nat Commun. 2014 Dec 15;5:5811. doi: 10.1038/ncomms6811.

29.

Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition.

Jiang L, Xiao L, Sugiura H, Huang X, Ali A, Kuro-o M, Deberardinis RJ, Boothman DA.

Oncogene. 2015 Jul 23;34(30):3908-16. doi: 10.1038/onc.2014.321. Epub 2014 Oct 6.

30.

ATM regulates insulin-like growth factor 1-secretory clusterin (IGF-1-sCLU) expression that protects cells against senescence.

Luo X, Suzuki M, Ghandhi SA, Amundson SA, Boothman DA.

PLoS One. 2014 Jun 17;9(6):e99983. doi: 10.1371/journal.pone.0099983. eCollection 2014.

31.

The transcription factor TFII-I promotes DNA translesion synthesis and genomic stability.

Fattah FJ, Hara K, Fattah KR, Yang C, Wu N, Warrington R, Chen DJ, Zhou P, Boothman DA, Yu H.

PLoS Genet. 2014 Jun 12;10(6):e1004419. doi: 10.1371/journal.pgen.1004419. eCollection 2014 Jun.

32.

Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair.

Morales JC, Richard P, Rommel A, Fattah FJ, Motea EA, Patidar PL, Xiao L, Leskov K, Wu SY, Hittelman WN, Chiang CM, Manley JL, Boothman DA.

Nucleic Acids Res. 2014 Apr;42(8):4996-5006. doi: 10.1093/nar/gku160. Epub 2014 Mar 3.

33.

Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.

Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, Gao J, Boothman DA.

Crit Rev Eukaryot Gene Expr. 2014;24(1):15-28. Review.

34.

Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.

Ma X, Huang X, Huang G, Li L, Wang Y, Luo X, Boothman DA, Gao J.

Adv Healthc Mater. 2014 Aug;3(8):1210-6. doi: 10.1002/adhm.201300590. Epub 2014 Feb 14.

35.

Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.

Cao L, Li LS, Spruell C, Xiao L, Chakrabarti G, Bey EA, Reinicke KE, Srougi MC, Moore Z, Dong Y, Vo P, Kabbani W, Yang CR, Wang X, Fattah F, Morales JC, Motea EA, Bornmann WG, Yordy JS, Boothman DA.

Antioxid Redox Signal. 2014 Jul 10;21(2):237-50. doi: 10.1089/ars.2013.5462. Epub 2014 Apr 3.

36.

EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.

Li L, Puliyappadamba VT, Chakraborty S, Rehman A, Vemireddy V, Saha D, Souza RF, Hatanpaa KJ, Koduru P, Burma S, Boothman DA, Habib AA.

Oncogene. 2015 Jan 2;34(1):129-134. doi: 10.1038/onc.2013.534. Epub 2013 Dec 23.

37.

An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.

Li L, Chakraborty S, Yang CR, Hatanpaa KJ, Cipher DJ, Puliyappadamba VT, Rehman A, Jiwani AJ, Mickey B, Madden C, Raisanen J, Burma S, Saha D, Wang Z, Pingle SC, Kesari S, Boothman DA, Habib AA.

Oncogene. 2014 Aug 14;33(33):4253-64. doi: 10.1038/onc.2013.400. Epub 2013 Sep 30.

38.

Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch.

Puliyappadamba VT, Chakraborty S, Chauncey SS, Li L, Hatanpaa KJ, Mickey B, Noorani S, Shu HK, Burma S, Boothman DA, Habib AA.

Cell Rep. 2013 Aug 29;4(4):764-75. doi: 10.1016/j.celrep.2013.07.025. Epub 2013 Aug 22.

39.

Cytoplasmic TRADD confers a worse prognosis in glioblastoma.

Chakraborty S, Li L, Tang H, Xie Y, Puliyappadamba VT, Raisanen J, Burma S, Boothman DA, Cochran B, Wu J, Habib AA.

Neoplasia. 2013 Aug;15(8):888-97.

40.

Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.

Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, Li LS, Patel M, Cao L, Moore Z, Rommel A, Boatman M, Lewis C, Euhus DM, Bornmann WG, Buchsbaum DJ, Spitz DR, Gao J, Boothman DA.

Mol Cancer Ther. 2013 Oct;12(10):2110-20. doi: 10.1158/1535-7163.MCT-12-0962. Epub 2013 Jul 24.

41.

The mechanism of DAB2IP in chemoresistance of prostate cancer cells.

Wu K, Xie D, Zou Y, Zhang T, Pong RC, Xiao G, Fazli L, Gleave M, He D, Boothman DA, Hsieh JT.

Clin Cancer Res. 2013 Sep 1;19(17):4740-9. doi: 10.1158/1078-0432.CCR-13-0954. Epub 2013 Jul 9.

42.

Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.

Kim H, Rigell CJ, Zhai G, Lee SK, Samuel SL, Martin A, Umphrey HR, Stockard CR, Beasley TM, Buchsbaum DJ, Li LS, Boothman DA, Zinn KR.

Mol Imaging Biol. 2014 Feb;16(1):85-94. doi: 10.1007/s11307-013-0665-4. Epub 2013 Jul 9.

43.

Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy.

Huang G, Chen H, Dong Y, Luo X, Yu H, Moore Z, Bey EA, Boothman DA, Gao J.

Theranostics. 2013;3(2):116-26. doi: 10.7150/thno.5411. Epub 2013 Feb 1.

44.

Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression.

Lo KK, Bey EA, Patra B, Benson DD, Boothman DA, Silliman CC, Barnett CC Jr.

Ann Surg Oncol. 2013 Jun;20(6):2073-7. doi: 10.1245/s10434-012-2842-0. Epub 2013 Jan 18.

45.

An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.

Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, Patel M, Parkinson EI, Wang Y, Williams NS, Gao J, Hergenrother PJ, Boothman DA.

Cancer Res. 2012 Jun 15;72(12):3038-47. doi: 10.1158/0008-5472.CAN-11-3135. Epub 2012 Apr 24.

46.

Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect.

Klokov D, Leskov K, Araki S, Zou Y, Goetz EM, Luo X, Willson D, Boothman DA.

Oncogene. 2013 Jan 24;32(4):479-90. doi: 10.1038/onc.2012.64. Epub 2012 Mar 5.

47.

Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery.

Yu H, Zou Y, Wang Y, Huang X, Huang G, Sumer BD, Boothman DA, Gao J.

ACS Nano. 2011 Nov 22;5(11):9246-55. doi: 10.1021/nn203503h. Epub 2011 Nov 1.

48.

CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor.

Leskov KS, Araki S, Lavik JP, Gomez JA, Gama V, Gonos ES, Trougakos IP, Matsuyama S, Boothman DA.

J Biol Chem. 2011 Nov 18;286(46):40083-90. doi: 10.1074/jbc.M111.252957. Epub 2011 Sep 27.

49.

Improved protein arrays for quantitative systems analysis of the dynamics of signaling pathway interactions.

Wang X, Dong Y, Jiwani AJ, Zou Y, Pastor J, Kuro-O M, Habib AA, Ruan M, Boothman DA, Yang CR.

Proteome Sci. 2011 Sep 15;9:53. doi: 10.1186/1477-5956-9-53.

50.

Photoactivation switch from type II to type I reactions by electron-rich micelles for improved photodynamic therapy of cancer cells under hypoxia.

Ding H, Yu H, Dong Y, Tian R, Huang G, Boothman DA, Sumer BD, Gao J.

J Control Release. 2011 Dec 20;156(3):276-80. doi: 10.1016/j.jconrel.2011.08.019. Epub 2011 Aug 23.

Supplemental Content

Loading ...
Support Center